Navann Ty
Stock Analyst at Exane BNP Paribas
(1.79)
# 1,971
Out of 4,433 analysts
11
Total ratings
61.9%
Success rate
19.64%
Average return
Main Sectors:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVNC Revance Therapeutics | Upgrades: Neutral | $20 | $3.16 | +532.91% | 1 | Aug 16, 2023 | |
| KVUE Kenvue | Initiates: Neutral | $28 | $20.60 | +35.92% | 1 | May 30, 2023 | |
| ALKS Alkermes | Maintains: Neutral | $22 → $26 | $24.46 | +6.30% | 2 | Mar 22, 2022 | |
| VTRS Viatris | Maintains: Neutral | $16 → $11 | $11.02 | -0.18% | 2 | Mar 10, 2022 | |
| ZTS Zoetis | Maintains: Neutral | n/a | $173.71 | - | 2 | Dec 20, 2021 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | n/a | $110.49 | - | 1 | Oct 5, 2021 | |
| OGN Organon & Co. | Initiates: Buy | n/a | $21.52 | - | 2 | Jul 23, 2021 |
Revance Therapeutics
Aug 16, 2023
Upgrades: Neutral
Price Target: $20
Current: $3.16
Upside: +532.91%
Kenvue
May 30, 2023
Initiates: Neutral
Price Target: $28
Current: $20.60
Upside: +35.92%
Alkermes
Mar 22, 2022
Maintains: Neutral
Price Target: $22 → $26
Current: $24.46
Upside: +6.30%
Viatris
Mar 10, 2022
Maintains: Neutral
Price Target: $16 → $11
Current: $11.02
Upside: -0.18%
Zoetis
Dec 20, 2021
Maintains: Neutral
Price Target: n/a
Current: $173.71
Upside: -
Jazz Pharmaceuticals
Oct 5, 2021
Initiates: Buy
Price Target: n/a
Current: $110.49
Upside: -
Organon & Co.
Jul 23, 2021
Initiates: Buy
Price Target: n/a
Current: $21.52
Upside: -